Ipca Laboratories Zukünftiges Wachstum
Future Kriterienprüfungen 2/6
Ipca Laboratories wird ein jährliches Gewinn- und Umsatzwachstum von 17.3% bzw. 10.5% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 17.3% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 15.8% betragen.
Wichtige Informationen
17.3%
Wachstumsrate der Gewinne
17.27%
EPS-Wachstumsrate
| Pharmaceuticals Gewinnwachstum | 16.2% |
| Wachstumsrate der Einnahmen | 10.5% |
| Zukünftige Eigenkapitalrendite | 15.82% |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 09 Jul 2026 |
Jüngste Aktualisierungen zum künftigen Wachstum
Analyseartikel • Feb 18
Here's What Analysts Are Forecasting For Ipca Laboratories Limited (NSE:IPCALAB) After Its Third-Quarter Results
It's been a good week for Ipca Laboratories Limited ( NSE:IPCALAB ) shareholders, because the company has just released...Analyseartikel • Aug 15
The Ipca Laboratories Limited (NSE:IPCALAB) First-Quarter Results Are Out And Analysts Have Published New Forecasts
NSEI:IPCALAB 1 Year Share Price vs Fair Value Explore Ipca Laboratories's Fair Values from the Community and select...Recent updates
Narrative-Update • Jul 03
IPCALAB: Lower Margin Outlook Will Pressure Upcoming Results And Dividend Decision
Analysts have adjusted their price target for Ipca Laboratories to ₹1,517.62 from ₹1,415.37, reflecting updated assumptions for slightly lower revenue growth, a reduced profit margin, and a lower future P/E multiple. What’s in the News for Ipca Laboratories Board meeting scheduled for May 29, 2026 to consider standalone and consolidated audited financial results for the fourth quarter and full financial year ended March 31, 2026.
Narrative-Update • Jun 19
IPCALAB: Upcoming Board Results And Dividend Move Will Reinforce Bullish View
Analysts have lifted their price target for Ipca Laboratories stock to ₹1,720 from ₹1,655, reflecting updated assumptions that combine slightly different views on revenue growth, profit margins and future P/E levels. What’s in the News for Ipca Laboratories A board meeting of Ipca Laboratories is scheduled for May 29, 2026, to review standalone and consolidated audited financial results for the fourth quarter and full year ended March 31, 2026.
Narrative-Update • Jun 04
IPCALAB: Higher Fair Value And Board Review Will Support Future Upside Potential
Analysts now set a higher fair value price target for Ipca Laboratories at ₹1,887, compared with ₹1,731 earlier, reflecting updated assumptions on revenue growth, profit margins and future P/E levels. What's in the News A board meeting is scheduled for May 29, 2026, to review standalone and consolidated audited financial results for the fourth quarter and full year ended March 31, 2026.Analyseartikel • Jun 03
Should You Be Adding Ipca Laboratories (NSE:IPCALAB) To Your Watchlist Today?
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Narrative-Update • May 06
IPCALAB: Upcoming Results And Dividend Decision Will Shape Earnings Visibility
Analysts have nudged their fair value estimate for Ipca Laboratories slightly higher from ₹1,406.78 to ₹1,415.37, reflecting updated assumptions around revenue growth, profit margin and future P/E. What's in the News A board meeting is scheduled for May 29, 2026 to review standalone and consolidated audited financial results for the quarter and financial year ended March 31, 2026 (company filing).Narrative-Update • Apr 19
IPCALAB: Upcoming Results And Revised Assumptions Will Guide Earnings Visibility
Analysts have trimmed their fair value estimate for Ipca Laboratories slightly from about ₹1,416 to around ₹1,407, reflecting updated assumptions on future revenue growth, profit margins and a modestly lower future P/E multiple. What's in the News Board meeting scheduled on February 13, 2026, to consider and take on record the standalone unaudited financial results for the third quarter and nine months ended December 31, 2025 (company filing).Narrative-Update • Apr 05
IPCALAB: Upcoming Unaudited Results Will Support Bullish View On Steady Fair Value
Analysts have kept their fair value estimate for Ipca Laboratories steady at ₹1,655, reflecting unchanged assumptions around discount rate, revenue growth, profit margin and future P/E expectations. What's in the News A board meeting is scheduled for February 13, 2026 to consider and record the standalone unaudited financial results for the third quarter ended December 31, 2025 (Key Developments).Narrative-Update • Mar 22
IPCALAB: Upcoming Results Review And Margins Outlook Will Support Steady Fair Value
Analysts now set their fair value estimate for Ipca Laboratories at about ₹1,655, up from roughly ₹1,634. This reflects updated assumptions that include a slightly higher profit margin and P/E multiple, along with modest adjustments to projected revenue growth and an unchanged discount rate.Narrative-Update • Mar 07
IPCALAB: Upcoming Results And Revised Assumptions Will Shape Future Earnings Visibility
Analysts have raised their fair value estimate for Ipca Laboratories from ₹1,106 to about ₹1,416, reflecting updated assumptions on discount rates, revenue growth, profit margins and future P/E that they consider to more accurately capture the company’s earnings potential. What's in the News A board meeting is scheduled for February 13, 2026, to review and take on record the standalone and consolidated unaudited financial results for the third quarter and nine months ended December 31, 2025 (Key Developments).Narrative-Update • Feb 20
IPCALAB: Upcoming Board Results Review Will Support Upbeat Long Term Outlook
Analysts have nudged their fair value estimate for Ipca Laboratories up from about ₹1,565 to roughly ₹1,634, reflecting updated assumptions around revenue growth, profit margins and a higher future P/E multiple. What's in the News Board meeting scheduled for February 13, 2026, to review and take on record the standalone unaudited financial results for the third quarter and nine months ended December 31, 2025.Analyseartikel • Feb 18
Here's What Analysts Are Forecasting For Ipca Laboratories Limited (NSE:IPCALAB) After Its Third-Quarter Results
It's been a good week for Ipca Laboratories Limited ( NSE:IPCALAB ) shareholders, because the company has just released...Analyseartikel • Feb 12
Does Ipca Laboratories (NSE:IPCALAB) Have A Healthy Balance Sheet?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Narrative-Update • Feb 06
IPCALAB: Upcoming Results Review Will Support Measured Outlook And Modest Assumption Shifts
Analysts have nudged their price target for Ipca Laboratories slightly higher, citing modest tweaks to fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News A board meeting is scheduled for February 13, 2026, to consider and record standalone unaudited financial results for the third quarter ended December 31, 2025.Narrative-Update • Jan 23
IPCALAB: Firmer Margins And Tighter P E Will Support Future Upside Potential
Analysts have inched up their fair value estimate for Ipca Laboratories to ₹1,731 per share from ₹1,730 per share, citing updated assumptions around revenue growth, profit margins and a slightly lower future P/E multiple in their models. What's in the News Board meeting scheduled for February 13, 2026, to consider and record standalone and consolidated unaudited financial results for the third quarter and nine months ended December 31, 2025 (company filing).Analyseartikel • Jan 21
Ipca Laboratories Limited's (NSE:IPCALAB) Earnings Haven't Escaped The Attention Of Investors
With a price-to-earnings (or "P/E") ratio of 45.1x Ipca Laboratories Limited ( NSE:IPCALAB ) may be sending very...Narrative-Update • Jan 08
IPCALAB: Board Meeting Schedule And Stable Assumptions Will Shape Balanced Outlook
Analysts have slightly raised their price target on Ipca Laboratories to ₹1,555 from ₹1,552, citing small adjustments to long term assumptions on revenue growth, profit margin and future P/E multiples. What's in the News Board meeting scheduled on Oct 17, 2025, at 17:00 Indian Standard Time (company filing) Board meeting set for Nov 13, 2025, to consider and record Standalone and Consolidated Unaudited Financial Results for the 2nd quarter and half year ended Sep 30, 2025 (company filing) Valuation Changes Fair Value: The analyst fair value estimate has moved marginally higher from ₹1,551.82 to ₹1,555.06 per share.Narrative-Update • Dec 24
IPCALAB: Improved Margins And Lower Multiple Will Support Future Upside Potential
Analysts have trimmed their price target on Ipca Laboratories by approximately ₹80 to around ₹1,730, reflecting slightly softer revenue growth assumptions, while still factoring in improved profit margins and a lower future P/E multiple. What's in the News Board meeting scheduled on October 17, 2025, at 17:00 IST to discuss corporate matters and ongoing strategic priorities (company filing).Narrative-Update • Dec 10
IPCALAB: Biosimilar Partnership And Board Meetings Will Shape Balanced Outlook
Analysts have nudged their price target for Ipca Laboratories slightly higher to approximately ₹1,552 from about ₹1,543, reflecting modestly improved valuation multiples, even though there were only minor trims to long term revenue growth and profit margin assumptions. What's in the News Ipca Laboratories and BioSimilar Sciences PR LLC entered a Technology Transfer and Joint Development Agreement to shift late stage development, clinical manufacturing, and commercial supply of a next generation anti cancer or anti inflammatory monoclonal antibody biosimilar to BSS sterile campus in Aguadilla, Puerto Rico (company announcement) A board meeting is scheduled on October 17, 2025, at 17:00 Indian Standard Time to review corporate matters (company filing) A board meeting is set for November 13, 2025, to consider and take on record the standalone and consolidated unaudited financial results for the second quarter and half year ended September 30, 2025 (company filing) Valuation Changes Fair Value Estimate has risen slightly from around ₹1,543 to about ₹1,552, reflecting a modestly higher intrinsic value.Analyseartikel • Dec 09
Is Now The Time To Put Ipca Laboratories (NSE:IPCALAB) On Your Watchlist?
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Narrative-Update • Nov 26
IPCALAB: Technology Partnership and Upcoming Board Meetings Will Influence Outlook
Narrative Update on Ipca Laboratories Analysts have raised their price target for Ipca Laboratories from ₹1,529.94 to ₹1,542.56. This change reflects optimism due to improved forecasts for revenue growth and profit margins.Narrative-Update • Nov 11
IPCALAB: Technology Agreement With BioSimilar Sciences Will Drive Future Expansion
Analysts have raised their price target for Ipca Laboratories from ₹1,501.41 to ₹1,529.94, citing updated model assumptions and slight adjustments to long-term growth and margin forecasts. What's in the News Ipca Laboratories held a Board Meeting on October 17, 2025, at 17:00 Indian Standard Time.Analyseartikel • Oct 19
Shareholders Should Be Pleased With Ipca Laboratories Limited's (NSE:IPCALAB) Price
When close to half the companies in India have price-to-earnings ratios (or "P/E's") below 27x, you may consider Ipca...Analyseartikel • Sep 05
If EPS Growth Is Important To You, Ipca Laboratories (NSE:IPCALAB) Presents An Opportunity
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Analyseartikel • Aug 15
The Ipca Laboratories Limited (NSE:IPCALAB) First-Quarter Results Are Out And Analysts Have Published New Forecasts
NSEI:IPCALAB 1 Year Share Price vs Fair Value Explore Ipca Laboratories's Fair Values from the Community and select...
Neues Narrative • Dec 12
Synergies With Unichem Laboratories And US Market Re-entry Will Boost Future Earnings
Strong domestic formulation growth and market share improvement position Ipca Laboratories for increased revenues and earnings.Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 3/31/2029 | 132,985 | 19,471 | 14,641 | 20,073 | 5 |
| 3/31/2028 | 120,078 | 16,697 | 10,997 | 17,079 | 14 |
| 3/31/2027 | 107,687 | 14,000 | 9,492 | 14,590 | 16 |
| 3/31/2026 | 96,472 | 11,411 | 4,860 | 11,420 | N/A |
| 12/31/2025 | 95,062 | 9,099 | N/A | N/A | N/A |
| 9/30/2025 | 93,590 | 8,317 | 4,697 | 13,618 | N/A |
| 6/30/2025 | 91,574 | 7,787 | N/A | N/A | N/A |
| 3/31/2025 | 89,412 | 7,377 | 5,458 | 13,213 | N/A |
| 12/31/2024 | 87,268 | 7,295 | N/A | N/A | N/A |
| 9/30/2024 | 85,343 | 6,612 | 8,970 | 14,414 | N/A |
| 6/30/2024 | 82,133 | 5,768 | N/A | N/A | N/A |
| 3/31/2024 | 77,059 | 5,474 | 5,334 | 9,447 | N/A |
| 12/31/2023 | 71,875 | 5,643 | N/A | N/A | N/A |
| 9/30/2023 | 66,806 | 4,922 | 2,606 | 6,767 | N/A |
| 6/30/2023 | 62,500 | 4,911 | N/A | N/A | N/A |
| 3/31/2023 | 62,481 | 4,713 | 3,113 | 8,058 | N/A |
| 12/31/2022 | 60,225 | 5,250 | N/A | N/A | N/A |
| 9/30/2022 | 59,070 | 6,142 | 2,398 | 7,616 | N/A |
| 6/30/2022 | 58,505 | 7,205 | N/A | N/A | N/A |
| 3/31/2022 | 58,305 | 8,841 | 3,771 | 8,561 | N/A |
| 12/31/2021 | 56,561 | 9,152 | N/A | N/A | N/A |
| 9/30/2021 | 56,355 | 9,837 | 3,728 | 8,554 | N/A |
| 6/30/2021 | 54,521 | 10,005 | N/A | N/A | N/A |
| 3/31/2021 | 54,207 | 11,400 | 7,286 | 10,901 | N/A |
| 12/31/2020 | 53,802 | 10,647 | N/A | N/A | N/A |
| 9/30/2020 | 51,833 | 9,968 | 7,371 | 10,767 | N/A |
| 6/30/2020 | 51,061 | 9,228 | N/A | N/A | N/A |
| 3/31/2020 | 46,499 | 6,063 | 2,641 | 5,704 | N/A |
| 12/31/2019 | 44,563 | 6,189 | N/A | N/A | N/A |
| 9/30/2019 | 42,496 | 5,804 | N/A | 5,181 | N/A |
| 6/30/2019 | 39,777 | 5,059 | N/A | N/A | N/A |
| 3/31/2019 | 37,750 | 4,448 | N/A | 5,010 | N/A |
| 3/31/2018 | 32,852 | 2,394 | N/A | 3,411 | N/A |
| 3/31/2017 | 31,562 | 1,945 | N/A | 2,819 | N/A |
| 3/31/2016 | 28,671 | 931 | N/A | 7,087 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: IPCALABDas prognostizierte Gewinnwachstum (17.3% pro Jahr) liegt über der Sparquote (6.9%).
Ertrag vs. Markt: IPCALABDie Erträge des Unternehmens (17.3% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Indian (16.3% pro Jahr).
Hohe Wachstumserträge: IPCALABDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.
Einnahmen vs. Markt: IPCALABDie Einnahmen des Unternehmens (10.5% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt Indian (11.1% pro Jahr).
Hohe Wachstumseinnahmen: IPCALABDie Einnahmen des Unternehmens (10.5% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: IPCALABDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (15.8%).
Wachstumsunternehmen entdecken
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/07/13 20:51 |
| Aktienkurs zum Tagesende | 2026/07/13 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2026/03/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Ipca Laboratories Limited wird von 38 Analysten beobachtet. 16 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| Aditya Khemka | Ambit Capital |
| null null | Anand Rathi Shares and Stock Brokers Limited |